Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PPARδ agonist 9 (compound 21), with an EC50 of 3.6 nM, is effective in vivo, decreasing serum MCP-1 concentrations in mice and markedly reducing atherosclerotic development in the LDLr-KO model with an inhibition rate of 50-60% [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | PPARδ agonist 9 (compound 21), with an EC50 of 3.6 nM, is effective in vivo, decreasing serum MCP-1 concentrations in mice and markedly reducing atherosclerotic development in the LDLr-KO model with an inhibition rate of 50-60% [1]. |
Molecular Weight | 569.04 |
Formula | C26H28ClF3N4O3S |
CAS No. | 928023-21-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PPARδ agonist 9 928023-21-6 DNA Damage/DNA Repair Metabolism PPAR inhibitor inhibit